Nuvilex (NASDAQ:PMCB) Posts Earnings Results

Nuvilex (NASDAQ:PMCB) issued its quarterly earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, FiscalAI reports.

Nuvilex Stock Performance

NASDAQ:PMCB opened at $0.69 on Wednesday. Nuvilex has a one year low of $0.63 and a one year high of $1.73. The stock has a market cap of $7.41 million, a PE ratio of -0.50 and a beta of 0.33. The stock has a 50 day moving average price of $0.78 and a 200 day moving average price of $0.87.

Insiders Place Their Bets

In related news, CEO Joshua Silverman acquired 40,000 shares of the stock in a transaction on Wednesday, January 7th. The shares were bought at an average price of $0.83 per share, with a total value of $33,200.00. Following the completion of the purchase, the chief executive officer owned 416,250 shares of the company’s stock, valued at approximately $345,487.50. This represents a 10.63% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired a total of 110,000 shares of company stock worth $89,000 over the last quarter. Insiders own 10.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Nuvilex to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.